Corventis never seemed liked more than the newest toy. What is formidable is Cardionet's infra-structure and 5 year lead in the space. There will be other toys in the space but that's the easy part. The tough part is creating the national infra-structure to support it, develop the clinical trials and build physician support. Of yes, and then get reimbursement. Cardionet should likely continue to increase their lead. The thing most people don't understand is that developing the device may be the easy part.